| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| 1g | |||
| Other Sizes |
Fipexide (Attentil, Vigilor) is a psychoactive drug of the piperazine class. It is a parachloro-phenossiacetic acid derivative acting as a nootropic agent. It was developed in Italy in 1983. It was used in Italy and France for the treatment of senile dementia but is no longer in common use due to undesirable side effects including fever and hepatitis.
| ln Vitro |
In Arabidopsis wild-type seedlings, fipexide (50 μM) exhibits a simple structure with areas of active division and epidermal sections with fully expanded cells [2].
- Fipexide (FPX) acts as a novel chemical inducer in plants. In vitro culture of Arabidopsis thaliana cotyledons and hypocotyls showed that Fipexide (0.1-10 μM) dose-dependently promoted callus formation and shoot regeneration. At 1 μM, it increased the shoot regeneration rate by ~40% compared with the control group (MS medium without FPX). It also enhanced callus induction efficiency in Nicotiana tabacum leaf explants [2] - Fipexide (1 μM) upregulated the expression of shoot regeneration-related genes (WUSCHEL, STM) in Arabidopsis callus cells (detected by qPCR), without affecting cell viability (Evans blue staining) [2] |
|---|---|
| ln Vivo |
Fipexide (10 mg/kg; oral; 5–10 days) totally removes convulsion-related memory impairments[3].
- In rats subjected to cognitive impairment models (age-related or scopolamine-induced), oral administration of Fipexide (10, 20 mg/kg/day) for 21 days improved cognitive functions. Behavioral tests (Morris water maze, passive avoidance task) showed that Fipexide-treated rats exhibited shorter escape latency (by ~30% at 20 mg/kg) and longer retention latency (by ~50% at 20 mg/kg) compared with the control group. Neurochemical analysis revealed increased choline acetyltransferase (ChAT) activity and acetylcholine (ACh) levels in the cerebral cortex and hippocampus (detected by colorimetric assay and HPLC) [1] - In PTZ-kindled amnesic rats, intraperitoneal injection of Fipexide (5, 10 mg/kg) 30 minutes before each PTZ administration (3 times/week for 10 weeks) prevented memory impairment. Passive avoidance task results showed that the retention latency of Fipexide-treated rats (10 mg/kg) was significantly longer than that of the PTZ-only group, with no effect on PTZ-induced convulsions [3] |
| Cell Assay |
- Plant cell callus formation and shoot regeneration assay: Arabidopsis thaliana cotyledons/hypocotyls or Nicotiana tabacum leaf explants were surface-sterilized and cut into small segments. Explants were inoculated on MS medium supplemented with Fipexide (0.1, 1, 10 μM) and auxin (2,4-D) for callus induction. After 2 weeks, callus was transferred to shoot induction medium containing Fipexide and cytokinin (BA). Callus induction rate and shoot regeneration rate were calculated after 4 weeks of culture. For gene expression analysis, callus tissues were collected, total RNA was extracted, and qPCR was performed to detect WUSCHEL and STM mRNA levels [2]
|
| Animal Protocol |
Animal/Disease Models: Ignite rats[3]
Doses: 10 mg/kg Route of Administration: oral; 5-10 Day Experimental Results:Complete elimination of memory defects caused by ignition. Antagonizes the amnestic effects of pentylenetetrazol (PTZ) ignition. - Cognitive improvement model: Adult rats were randomly divided into control, scopolamine-induced (1 mg/kg, intraperitoneal injection) model, and Fipexide treatment groups (10, 20 mg/kg/day, oral gavage). Treatment lasted for 21 days, with scopolamine administered 30 minutes before behavioral tests (Morris water maze, passive avoidance task). After behavioral tests, rats were sacrificed, and cerebral cortex/hippocampus tissues were collected for ChAT activity and ACh level detection [1] - PTZ-kindled amnesia model: Rats were randomly divided into control, PTZ-kindled (35 mg/kg, intraperitoneal injection, 3 times/week for 10 weeks), and Fipexide treatment groups (5, 10 mg/kg, intraperitoneal injection 30 minutes before each PTZ administration). After kindling, passive avoidance task was performed to evaluate memory function. Convulsion severity was scored during PTZ administration [3] |
| References |
|
| Additional Infomation |
1-[4-(1,3-benzodioxane-5-ylmethyl)-1-piperazinyl]-2-(4-chlorophenoxy)acetone belongs to the benzodioxane class of compounds. - Phipexide is a synthetic compound with dual biological activity in both animals and plants [1][2][3] - Its core mechanisms include: in mammals, regulating the cholinergic system (increasing ChAT activity and ACh levels) to improve cognitive function and prevent amnesia [1][3]; in plants, upregulating bud regeneration-related genes to promote callus formation and bud regeneration, and serving as a cytokinin alternative in tissue culture [2] - Phipexide has shown potential application value as a cognitive enhancer in the treatment of age-related or drug-induced cognitive impairment, and as a plant tissue culture inducer for crop improvement and plant biotechnology [1][2][3].
|
| Molecular Formula |
C20H21N2O4CL.HCL
|
|---|---|
| Molecular Weight |
425.30568
|
| Exact Mass |
388.119
|
| CAS # |
34161-24-5
|
| Related CAS # |
Fipexide hydrochloride;34161-23-4
|
| PubChem CID |
3351
|
| Appearance |
White to off-white solid powder
|
| Density |
1.342g/cm3
|
| Boiling Point |
559.3ºC at 760mmHg
|
| Flash Point |
292.1ºC
|
| LogP |
2.667
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
27
|
| Complexity |
492
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
BFUJHVVEMMWLHC-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H21ClN2O4/c21-16-2-4-17(5-3-16)25-13-20(24)23-9-7-22(8-10-23)12-15-1-6-18-19(11-15)27-14-26-18/h1-6,11H,7-10,12-14H2
|
| Chemical Name |
1-[4-(1,3-benzodioxol-5-ylmethyl)piperazin-1-yl]-2-(4-chlorophenoxy)ethanone
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~321.47 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.35 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.08 mg/mL (5.35 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (5.35 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3512 mL | 11.7561 mL | 23.5123 mL | |
| 5 mM | 0.4702 mL | 2.3512 mL | 4.7025 mL | |
| 10 mM | 0.2351 mL | 1.1756 mL | 2.3512 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
